青岛海尔生物医疗股份有限公司关于完成补选董事及调整董事会专门委员会委员的公告

Group 1 - The company held its first extraordinary general meeting of shareholders on November 17, 2025, where it approved the election of Mr. Hu Xiangde as a non-independent director of the third board of directors [2] - The adjustment of the specialized committees of the board was also approved during the meeting, ensuring smooth operations following the changes in board membership [3] - The composition of the board's specialized committees was detailed, including the Strategic and ESG Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee [3] Group 2 - The company announced the cancellation of part of the repurchased shares and a reduction in registered capital, with 1,459,586 shares being adjusted from employee stock ownership plans to cancellation [11] - Following the cancellation, the total number of shares will decrease from 317,952,508 to 316,492,922, representing a reduction of 0.46% of the total share capital [14] - The company aims to enhance investor returns and maintain the interests of shareholders through this capital reduction [11][14]